ArticleNature communications2026
Chondrocytes reprogram chromatin in hypoxic microenvironments to activate CADM1-AS1/HDAC1 complex-mediated anti-inflammation signals.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Maintaining chondrocyte homeostasis is crucial for the effective treatment of osteoarthritis. Chondrocytes reside in a hypoxic environment under physiological conditions. This study, conducted exclusively in male mice, examines the association between epigenetics and chondrocyte homeostasis and observes significant alterations in histone acetylation in chondrocytes under hypoxic conditions. We identify a key enhancer element that regulates the long non-coding RNA CADM1-AS1, which is essential for cartilage homeostasis. This work elucidates a mechanism of epigenetic modulation that contributes to chondrocyte dysfunction in osteoarthritis. Further mechanistic investigations show that CADM1-AS1 recruits histone deacetylase complexes to suppress the transcriptional activation of NOS2, thereby affecting amino acid metabolism in chondrocytes. Conditional knockout of CADM1-AS1 in chondrocytes accelerates osteoarthritis development in mice. Using a hybrid exosome delivery system, we successfully modulate the expression of CADM1-AS1 and effectively reduce cartilage damage. Collectively, these findings reveal the importance of epigenetic regulation via CADM1-AS1-mediated histone deacetylation in the pathogenesis of osteoarthritis. Thus, CADM1-AS1 represents a potential therapeutic target for reducing cartilage damage in osteoarthritis and improving disease management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.